TP53 and neoplasm: A recent study by Dayton et al. showed that PKM2 deletion in a KrasLSL−G12D/p53 driven sarcoma model results in delayed tumor onset, contradicting the importance of decreased PKM2 activity in tumor initiation (Dayton et al., 2018).